3-year relapse-free survival, overall survival and long-term toxicity of (neo)adjuvant ipilimumab + nivolumab in macroscopic stage III melanoma (OpACIN trial) - Blank, CU; Versluis, JM; Reijers, ILM (Ann Oncol, 2019)
et al.